ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Adjunctive topical bromfenac and the 3-year bevacizumab injection burden in macular edema secondary to branch retinal vein occlusion.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAnti-vascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion (BRVO) imposes a substantial long-term injection burden. We evaluated whether eyes prescribed adjunctive topical bromfenac required fewer intravitreal bevacizumab injections over 3 years than those receiving bevacizumab monotherapy.
methodsThis retrospective, nonconcurrent historical-control cohort study included 62 treatment-naïve eyes followed for 36 months under the same optical coherence tomography (OCT)-guided pro re nata protocol. Twenty-nine eyes received intravitreal bevacizumab alone during 2016-2019, whereas 33 received bevacizumab with adjunctive topical bromfenac during 2023-2026.
resultsThe adjunctive bromfenac group received fewer injections over 36 months than the bevacizumab monotherapy group (5.8 ± 2.5 vs. 8.9 ± 3.7; p < 0.001) and the association persisted after adjustment for baseline visual acuity, macular thickness, OCT biomarkers, and nonperfusion area (Poisson adjusted rate ratio 0.62; 95% confidence interval 0.50-0.77; p < 0.001). Best-corrected visual acuity and central macular thickness at 36 months did not differ significantly between the two groups.
conclusionAdjunctive topical bromfenac was associated with fewer bevacizumab injections over 36 months in BRVO-associated macular edema.
Indexed as
Identifiers
42909592What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.